220.127.116.11 Dopamine enzyme inhibitors / catechol-O-methyltransferase inhibitors (COMT inhibitors)
|1st choice||Entacapone tablets 200mg||Dose:|
200mg with each dose of levodopa with dopa-decarboxylase inhibitor; max 2g daily
|2nd choice||Tolcapone 100mg tablets||Dose: 100mg three times daily, leave 6 hours between each dose; max 200mg three times daily in exceptional circumstances; first daily dose should be taken at the same time as levodopa with dopa-decarboxylase inhibitor|
- COMT inhibitors are not recommended as first line agents for PD.
- There is no evidence to support their use as neuroprotective therapies.
- Entacapone or tolcapone may be used for management of motor fluctuations.
- A triple combination preparation of levodopa, caridopa and entacapone (Stalevo® or Sastravi®) may be suitable for patients requiring entacapone who are having problems with concordance. Sastravi® is currently the ‘branded generic’ combination preparation with the lowest acquisition cost.
- Due to the risk of hepatotoxicity, tolcapone should be prescribed under specialist supervision only, when other COMT inhibitors combined with co-beneldopa or co-careldopa are ineffective or not tolerated. LFT monitoring is required (see shared care guideline).
- Tolcapone should only be continued beyond three weeks if there is substantial improvement in symptom control.